Outcomes Research in Cardiovascular Disease

Working Group Agenda

September 30, 2002

National Heart, Lung, and Blood Institute

Rockledge 2 building, Suite 9100/9104

6701 Rockledge Drive,

Bethesda, MD 20817

Chair: Harlan Krumholz, MD, Yale University

Vice-Chair: Eric Peterson, MD, Duke University

Working Group Report

8:00 - 8:15 AM

8:15 - 8:30 AM

8:30 - 8:45 AM

The goals of outcomes research are closely aligned with a number of important government initiatives currently underway which seek to improve health care. The Institute of Medicine released a blueprint for improving health care delivery entitled, Crossing The Quality Chasm: A New Health System For The 21^st Century. This report identified safety, effectiveness, equity, efficiency, timeliness and patient-centeredness as the six core aims for improving the quality of care in the United States. The Working Group believes that these 6 aims can help define important targets for outcomes research in cardiovascular disease.

8:45-9:00 AM

For the purposes of this Working Group, "Outcomes Research" is defined as applied clinical research that generates knowledge to improve clinical decision-making and health-care delivery to optimize patient outcomes. Outcomes Research focuses particularly on providing evidence to assess and promote the effectiveness of therapeutic interventions, to enhance the migration of best practice to clinical practice, to elevate the quality of care, and to support the optimal allocation of resources for all patients. The research has direct, proximate, and immediate relationships to patient care and health-care delivery. Research addresses not only patterns of care, but also elucidates factors contributing to those patterns, and determines their consequences. The research also is directed toward developing strategies to address current deficiencies in knowledge or implementation directly relevant to clinical practice. Outcomes Research can employ methodology of non-experimental (observational) designs, as well as quasi-experimental or clinical trial approaches to test interventions, whichever is most suited to the specific research question.

9:00 - 10:30 Subcommittee reports and discussion

10:30 - 10:45 Break

10:45 - 12:15 Subcommittee reports and discussion (continued)

12:15 - 1:15 Lunch

1:15 - 2:00 Future directions and priority setting

2:00 - 2:30 Other Issues

2:30 - 3:30 Document discussion and priority setting

3:30 - 4:00 Closing Remarks and Action Plans

Planning Group

Working Group Members

Representatives of other government agencies: